TNX-102 SL + Placebo SL Tablet
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection
Conditions
Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19, Long COVID, Long Haul COVID
Trial Timeline
Aug 18, 2022 → Jul 27, 2023
NCT ID
NCT05472090About TNX-102 SL + Placebo SL Tablet
TNX-102 SL + Placebo SL Tablet is a phase 2 stage product being developed by Tonix Pharmaceuticals for Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT05472090. Target conditions include Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection, COVID-19, Long COVID.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05472090 | Phase 2 | Completed |
| NCT04508621 | Phase 3 | Completed |
| NCT04172831 | Phase 3 | Completed |
| NCT03062540 | Phase 3 | Terminated |
Competing Products
1 competing product in Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Nirmatrelvir + Placebo + Ritonavir | Pfizer | Phase 2 | 51 |